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We tested the feasibility of linking Active Bacterial Core 
surveillance, a prospective, population-based surveillance 
system for invasive bacterial disease, to a newborn dried 
blood spot (nDBS) repository. Using nDBS specimens, we 
resequenced CD46, putative host gene receptor for Neis-
seria meningitidis, and identiﬁ  ed variants associated with 
susceptibility to this disease.
H
ost genetic factors may help predict susceptibility to 
infectious diseases and could target high-risk popula-
tions for public health interventions such as vaccination. 
However, even with cost-effective genotyping technolo-
gies (1), small cohorts and limited associated epidemiolog-
ic data may lead to underpowered studies. Existing large 
population-based surveillance systems, if integrated with 
appropriate genetic material, could contribute crucial hy-
potheses and generate data to identify host factors underly-
ing infectious diseases.
Active Bacterial Core surveillance (ABCs) is a network 
of state health departments, academic institutions, and lo-
cal collaborators funded by the Centers for Disease Control 
and Prevention (CDC). This network conducts population-
based surveillance for invasive bacterial pathogens, includ-
ing encapsulated bacteria Haemophilus inﬂ  uenzae, Neis-
seria meningitides, and Streptococcus pneumoniae ( 2); 
the Minnesota Department of Health has been involved in 
ABCs since 1995. Use of ABCs data to identify potential 
genetic risk factors could identify high-risk groups for vac-
cination with conjugated polysaccharide vaccines targeted 
against encapsulated bacterial pathogens. In particular, N. 
meningitidis, the causative agent for meningococcal dis-
ease, has a baseline carriage rate of 5%–10% (3), a US in-
cidence of 1 case/100,000 persons (2,4), and a 10%–15% 
case-fatality rate (2). Given the epidemiology of N. menin-
gitidis and recent data suggesting a high sibling risk ratio 
(5), it is plausible that host factors (6) modify susceptibility 
or severity to meningococcal disease.
The Study
Although ABCs provides a unique epidemiologic con-
text for assessing host genetic risk factors for N. meningiti-
dis, host DNA is not collected. However, genetic material 
is collected prospectively from all infants through state-
based newborn dried blood spot (nDBS) programs (7). We 
cross-referenced ABCs data to the state’s nDBS repository 
to identify nDBSs from Minnesota ABCs case-patients and 
controls.
ABCs data were evaluated to identify cases of invasive 
encapsulated bacterial infection (H. inﬂ  uenzae, N. menin-
gitides, or S. pneumoniae) in persons born January 1, 1997, 
through December 31, 2000. Parents or guardians of case-
patients were contacted by mail for written consent (and 
where needed, childhood consent). ABCs data from case-
patients with parental consent and from case-patients who 
did not respond after 2 successive mailings were included 
in the study. Two controls, selected from among children 
with nDBSs, were matched per case by date of birth, race, 
and hospital of birth. ABCs data and case and control nDB-
Ss were stripped of linkage to personal identiﬁ  ers.
Human subject review and approval was obtained 
through CDC and the Minnesota Department of Health 
before study initiation. Once ABCs data and nDBSs were 
deidentiﬁ  ed, the CDC institutional review board closed the 
project, which enabled genomic studies with unidentiﬁ  able 
nDBS specimens. The University of Washington human 
subjects division subsequently granted a certiﬁ  cate of ex-
emption.
We identiﬁ  ed 486 cases of invasive disease: 22 with N. 
meningitidis, 19 with H. inﬂ  uenzae, and 445 with S. pneu-
moniae. One case-patient refused consent and was dropped 
from the study; 88 case-patients (18.1%) gave written con-
sent, and 397 (81.7%) did not respond after 2 mailings. The 
nDBSs were identiﬁ  ed for 406 (84%) case-patients. Among 
controls, 812 (100%) were matched to case-patients by date 
of birth and race, and 674 (83%) were matched by date of 
birth, race, and hospital of birth. A total of 22 N. menigiti-
dis case-patients and 44 controls with nDBSs deﬁ  ned the 
case–control (CC) study. Case-patient characteristics are 
shown in Table 1. No deaths were documented among the 
ABCs case-patients.
Genomic DNA was ampliﬁ  ed from 3-mm punches of 
1/2″ nDBSs by using multiple displacement techniques (8) 
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(Molecular Staging, Inc., New Haven, CT, USA). We rese-
quenced the CD46 gene (9), a putative host gene receptor 
for N. meningitidis (10,11), in 143 samples from 66 CC 
study samples and 77 Coriell Cell Repository (CCR; Cam-
den, NJ, USA) samples (online Technical Appendix, avail-
able from www.cdc.gov/EID/content/14/7/1138-Techapp.
pdf) (GenBank accession no. AY916779). Standard dye 
primer and termination sequencing with sequence assembly 
and polymorphism discovery was performed through the 
Program for Genomic Applications (National Heart, Lung, 
and Blood Institute, Bethesda, MD, USA) (Seattle SNPs 
[single nucleotide polymorphisms]) (12). Of 269 diallelic 
sites (SNPs), 173 (64%) were in the CC study samples and 
59 (34%) were unique to the CC study samples (Table 2, 
online Technical Appendix). Hardy-Weinberg equilibrium 
(HWE) was used to evaluate genotyping errors; most SNPs 
in CCR (97.6%) and CC study samples (96.5%) samples 
met HWE (p>0.05).
The overall genotyping call rate for nDBS CC study 
samples was 89.5% compared with 96.7% for cell line–de-
rived CCR DNAs (p<0.0001, by χ2 test). Among CC study 
samples, 62% had highly useable DNA quality as assigned 
by MSI after ampliﬁ  cation. The DNA quality rating pre-
dicted genotyping call rate (generalized linear model R2 = 
0.52, p<0.0001) with highly useable samples having a call 
rate of 93.9%.
Among 173 SNPs in the CC study samples, 116 (67%) 
were in case-patients, 146 (84.3%) in controls, and 89 
(51.15%) in both groups (Table 2). We grouped SNPs (mi-
nor allele frequency >5%) from the European-American 
CCR samples into bins on the basis of linkage disequi-
librium (r2>0.80) by using the LDSelect algorithm (13). 
Among 17 CD46 tagSNPs tested (each representing 1 bin), 
site 6420 (rs41317049) was signiﬁ  cantly associated with 
meningococcal disease (by Fisher exact test) assuming a 
general genotype model (separately comparing homozy-
gous major, heterozygous, and homozygous minor alleles; 
p = 0.0176) and a dominant genetic model (homozygous 
major allele vs. all others; p = 0.0440) (online Technical 
Appendix). Logistic regression showed that, adjusting for 
age and sex, SNP 6420 had borderline signiﬁ  cance (p = 
0.051), with increased odds of disease (odds ratio 4.38) 
for GT/GG versus TT genotypes (95% conﬁ  dence inter-
val 0.99–19.30). Given a sample size of 16 case-patients 
and 32 controls, a general genotype model is powered (α 
= 0.05, β = 0.80) to detect an odds ratio from 3.6 through 
6.6, depending on the minor allele frequency of the risk-
conferring SNP.
Conclusions
We integrated an active, population-based, prospective 
disease surveillance system post hoc with a population-
based, prospective nDBS repository to combine disease 
surveillance information with genetic specimens. Although 
nDBSs have been used to establish prevalence (14), nDBSs 
have not been linked post hoc to an extensive clinical/epi-
demiologic database for genetic hypothesis generation.
To test use of these nDBS specimens for hypothesis 
generation, we resequenced a potential meningococcal 
risk factor, the putative meningogoccal receptor CD46, for 
genetic variation discovery. Highly useable samples had 
genotyping call rates similar to those of cell-line extracted 
CCR DNA (94% vs. 97%). Furthermore, on the basis of 
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Table 1. Characteristics of 22 case-patients infected with 
Neisseria meningitidis
Characteristic Value
Female, no. (%)  11 (50.0) 
Race-ethnicity, no. (%) 
 White  16  (72.7) 
 Black  3  (13.6) 
 Asian  2  (9.1) 
 Other  1  (4.6) 
Mean age, d (range)  144 (9 d–3.4 y) 
Bacteremia with focus, no. (%)  12 (54.6) 
Meningitis, no. (%)  10 (45.5) 
Serogroup, no. (%) 
 B  10  (45.5) 
 C  5  (22.7) 
 Y  5  (22.7) 
 W135  1  (4.5) 
  Not groupable  1 (4.5) 
Table 2. Number of diallelic sites (SNPs) identified for CD46, by population* 
Population Sample size  No. SNPs† (population-specific SNPs)‡  No. common SNPs§ 
European American  23 93 (32)  58
African 24 130 (74)¶ 68
Asian 24 88 (30) 46
Hispanic 6 56 (3) 56
Study samples  66 173 (59)  66
Case-patients 22 116 (27) 70
Controls 44 146 (57) 
*SNPs, single nucleotide polymorphisms. 
†Includes SNPs and diallelic insertion/deletion polymorphisms (indels). 
‡No. SNPs identified in only that racial/ethnic population. 
§Common SNPs defined as having a minor allele frequency >5%. 
¶Two SNPs (sites 18924 and 28122) were specific to the African cohort but in regions not resequenced sufficiently in other populations. Additional 
genotyping is needed to conclusively identify these as African specific. HWE and similar allele frequencies between the CC study 
samples and CCR samples, we did not detect heterozygote 
bias. Ongoing studies are evaluating use of other technolo-
gies to genotype these samples.
We identiﬁ  ed an association between an SNP (6420; 
rs41317049) in the candidate gene CD46 and case status 
for N. meningitidis. The intronic location of SNP 6420 and 
existence of CD46 splicing isoforms (15) suggest a pos-
sible role of altered splicing. However, the genetic associa-
tion itself and any hypothesized mechanism require future 
replication studies to rule out alternative explanations of 
chance, population stratiﬁ  cation,  causality/susceptibility, 
or linkage disequilibrium.
Our results are novel, but this pilot study was powered 
for large genetic effects. Furthermore, the cohort was pri-
marily of European descent, and results were not adjusted 
for multiple comparisons. Given the surveillance target 
period and duration that Minnesota retained nDBS speci-
mens, our study cohort was children <5 years of age, the 
age range targeted for conjugate polysaccharide vaccines. 
With the growing importance of using nDBSs for genetic 
studies (7), future studies should assess whether this ap-
proach is generalizable. Use of existing large, surveillance 
databases linked to nDBS repositories will facilitate rep-
lication of the genetic association speciﬁ  cally, and more 
generally, evaluation of host genomics of susceptibility to 
infectious diseases.
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